Prof Tom John
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
374 Scholarly works
1 Projects
HIGHLIGHTS
2026
Journal article
Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.
DOI: 10.1158/1078-0432.CCR-25-09422026
Journal article
Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee
DOI: 10.1016/j.jtho.2026.1036432026
Journal article
Identifying High-Risk Stage I NSCLC: The Promises and Pitfalls of Tumor-Informed ctDNA
DOI: 10.1016/j.jtho.2026.1037062026
Journal article
Impacts of Multidisciplinary Lung Cancer Meeting Presentation in a Clinical Quality Registry
DOI: 10.1016/j.jtocrr.2026.1009842026
Journal article
Treatment Timeliness in Extensive-Stage SCLC and Impact on Survival: A Registry-Based Observational Study
DOI: 10.1016/j.jtocrr.2026.1009782026
Journal article
Recent Advances in Combined Medical and Surgical Therapy for Resectable NSCLC
DOI: 10.1002/resp.702382025
Research grants (ARC, NHMRC, MRFF)
A Registry-Based Randomised Trial of Radiotherapy in Advanced Lung Cancer
RECENT SCHOLARLY WORKS
2026
Journal article
PP01.56: Final, 6-Year Outcomes with First-Line (1L) Nivolumab Plus Ipilimumab Plus Chemotherapy (N I C) in Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) from CheckMate 9LA
DOI: 10.1016/j.jtho.2026.1037992026
Journal article
Abstract LB105: Translational analyses from the randomized phase 3 DREAM3R trial: DuRvalumab with chEmotherapy as first line treAtment in advanced pleural Mesothelioma
DOI: 10.1158/1538-7445.am2026-lb1052026
Journal article
Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials
DOI: 10.1016/j.lungcan.2025.1088912026
Journal article
Time to achieve response and depth of maximal tumor response as potential surrogates for overall survival in advanced non-small cell lung cancer
DOI: 10.1080/14796694.2026.2630984